AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35219302
Drug: 0.5% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% ropivacaine 40 ml (medium concentration group)
Trial: 35219302
Drug: 0.4% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% ropivacaine 40 ml (low concentration group)
Trial: 36853224
Drug: Antiplatelet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy
Trial: 34045378
Drug: Avoid antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoid antiplatelet therapy
Trial: 38750866
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg
Trial: 36058230
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate 5 mg/day for 24 h plus standard care
Trial: 32074369
Drug: Other Analgesics
RxNorm normalized name: OTHER ANALGESICS AND ANTIPYRETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other Analgesics (OA)
Trial: 36273173
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg encapsulated Xanthohumol (XN) per day
Trial: 33644992
Drug: Repository corticotropin
RxNorm normalized name: Repository Corticotropin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repository corticotropin injection (RCI) 80 U twice weekly during a 12-week open-label period, followed by either RCI or placebo for another 12 weeks.
Trial: 39666517
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment
Trial: 33068178
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (LLLT + 5% minoxidil)
Trial: 36099080
Drug: Informative talk
RxNorm normalized name: INFORMATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Informative talk supplemented with a 1200-word written information source about the HPV vaccine.
Trial: 34523814
Drug: Topical ocular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ocular dosing of GLH8NDE at doses of 9, 18, 36 mg (Koreans), and 36 mg (Whites)
Trial: 37158925
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 12 weeks
Trial: 32588050
Drug: Sodium zirconium
RxNorm normalized name: Sodium zirconium silicate
DrugBank: Sodium zirconium cyclosilicate (DB14048)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sodium zirconium cyclosilicate (SZC) 10g TID for 48 hours followed by maintenance therapy with SZC QD for ≤29 days
Trial: 32237024
Drug: Antenatal magnesium
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal magnesium sulphate (MgSO4) - loading dose of 5 g followed by 1 g/hour
Trial: 35987083
Drug: MIACT (Motivational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIACT (Motivational Interviewing plus Acceptance and Commitment Therapy)
Trial: 35987083
Drug: CC (Conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC (Conventional Care)
Trial: 33143883
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 mg kg−1 Cr)
Trial: 33143883
Drug: Cr 25
RxNorm normalized name: Paxil CR 25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr 25 mg kg−1
Trial: 33143883
Drug: Cr 50
RxNorm normalized name: Sinemet CR 50mg-200mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr 50 mg kg−1
Trial: 33143883
Drug: Cr 100
RxNorm normalized name: Luvox CR 100mg Extended-Release Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cr 100 mg kg−1
Trial: 35972855
Drug: Islatravir 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Islatravir 2.25 mg with doravirine and lamivudine
Trial: 32252548
Drug: Dabigatran dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran dual therapy (150 mg)
Trial: 32252548
Drug: Dabigatran dual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran dual therapy (110 mg)
Trial: 34825538
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy for insomnia
Trial: 34981829
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg every 2 weeks (Q2W)
Trial: 34981829
Drug: Secukinumab 300
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secukinumab 300 mg every 4 weeks (Q4W)
Trial: 34981829
Drug: Uptitration to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uptitration to Secukinumab 300 mg every 2 weeks (Q2W)
Trial: 35934140
Drug: JNJ‐10450232 (NTM‐006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐10450232 (NTM‐006) single doses (50–6000 mg)
Trial: 35934140
Drug: JNJ‐10450232 (NTM‐006)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ‐10450232 (NTM‐006) multiple doses (250–2500 mg twice daily for 8 days)
Trial: 33278071
Drug: 1 mL
RxNorm normalized name: ethanol 1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of salbutamol respirable solution nebulized by Aerogen Solo connected to Combihaler spacer with 2 puffs salbutamol MDI (200 µg salbutamol) before nebulisation
Trial: 32245781
Drug: High-hemoglobin group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-hemoglobin group (targeting hemoglobin levels of 11-13 g/dl)
Trial: 32245781
Drug: Low-hemoglobin group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-hemoglobin group (targeting hemoglobin levels of 9-11 g/dl)
Trial: 35970302
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (SOC; salvage chemoimmunotherapy followed by high-dose therapy with autologous stem cell rescue)
Trial: 34793718
Drug: 177Lu-Dotatate plus
RxNorm normalized name: 177Lu-dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 177Lu-Dotatate plus long-acting octreotide (7·4 GBq every 8 weeks, 30 mg intramuscularly)
Trial: 34793718
Drug: High-dose long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose long-acting octreotide (60 mg every 4 weeks)
Trial: 35636686
Drug: Succinylcholine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.5 mg/kg
Trial: 36246976
Drug: Laparoscopic parapelvic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laparoscopic parapelvic cyst topical decompression
Trial: 34591237
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg every 3 weeks
Trial: 34591237
Drug: chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Trial: 39499492
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: 34305809
Drug: Regular-dosage therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-dosage therapy
Trial: 37493287
Drug: Platelet-rich plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) injections
Trial: 35915317
Drug: TACE plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TACE plus Cidan Capsule (0.27 g/capsule, 5 capsules every time, 4 times a day for 6 months)
Trial: 36002874
Drug: Transcutaneous auricular
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous auricular vagus nerve stimulation (taVNS), two one-hour sessions daily for four weeks at suprathreshold intensities.
Trial: 33569570
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg QID elenbecestat
Trial: 32729923
Drug: High-nitrate beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-nitrate beetroot juice (∼400 mg nitrate) and folic acid (∼5 mg folic acid) (N + F)
Trial: 35511890
Drug: Losartan (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (daily oral starting at 25 mg, increasing every 8 weeks for 6 months)
Trial: 39661957
Drug: Enhanced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced treatment as usual
Trial: 33471739
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral calcium or calcitriol supplementation (test group)
Trial: 35491482
Drug: No β-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No β-blockers
Trial: 33205280
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg
Trial: 35887534
Drug: DehydraTECH2.0 CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DehydraTECH2.0 CBD formulation
Trial: 39636024
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo
Trial: 38689310
Drug: Continuous morphine
RxNorm normalized name: morphine sulfate Oral Suspension [MST Continus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous morphine
Trial: 32365226
Drug: Temsirolimus (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temsirolimus (25 mg weekly) plus Cetuximab (400/250 mg/m2 weekly)
Trial: 33932130
Drug: Midazolam 3
RxNorm normalized name: KETAMINE HYDROCHLORIDE 25 mg / MIDAZOLAM 3 mg / HYDROXYZINE HYDROCHLORIDE 10 mg SUBLINGUAL TROCHE [MKH Dose Pack]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 3 mg
Trial: 32030780
Drug: A annua
RxNorm normalized name: IVA ANNUA POLLEN
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A annua sublingual immunotherapy (SLIT) for 32 weeks
Trial: 32030780
Drug: A annua
RxNorm normalized name: IVA ANNUA POLLEN
DrugBank: Iva annua pollen (DB10927)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A annua sublingual immunotherapy (SLIT) for 16 weeks
Trial: 36297099
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous vitamin C (HDIVC)
Trial: 39418854
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT)
Trial: 35513899
Drug: Once-daily fixed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily fixed combination of Bimatoprost 0.01%, Brimonidine 0.15%, and Timolol 0.5%
Trial: 35150194
Drug: Technique A
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technique A (shallow injection/3 aliquots)
Trial: 33794353
Drug: Web-based Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based Drug Management Module (DMM)
Trial: 34087948
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil (OM) 25 mg modified release (MR) tablets under fed state
Trial: 34087948
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil (OM) 37.5 mg modified release (MR) tablets under fed state
Trial: 34087948
Drug: Omecamtiv mecarbil
RxNorm normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omecamtiv mecarbil (OM) 50 mg modified release (MR) tablets under fed state
Trial: 34087948
Drug: Two 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 25 mg OM MR tablets
Trial: 34226418
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg sugammadex
Trial: 33652234
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no thermal treatment)
Trial: 33444175
Drug: I-WOTCH multicomponent
RxNorm normalized name: iobenguane I-131
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I-WOTCH multicomponent self-management intervention for tapering opioid doses
Trial: 34600734
Drug: BDP/FF/GB 200/12/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB 200/12/25 ?g (therapeutic)
Trial: 34600734
Drug: BDP/FF/GB 400/12/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB 400/12/25 ?g (therapeutic)
Trial: 34600734
Drug: BDP/FF/GB 800/48/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP/FF/GB 800/48/100 ?g (supratherapeutic)
Trial: 34534429
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg) plus platinum-based chemotherapy (with or without bevacizumab)
Trial: 34534429
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus platinum-based chemotherapy (with or without bevacizumab)
Trial: 34584851
Drug: Waitlist control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist control condition, received delayed treatment at follow-up assessment.
Trial: 39660834
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy
Trial: 35915056
Drug: Multi-session Cognitive
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-session Cognitive Behavioral Therapy (CBT)
Trial: 38587237
Drug: Empagliflozin 10
RxNorm normalized name: empagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 10 mg daily
Trial: 35605625
Drug: Heterologous booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·1 mL)
Trial: 35605625
Drug: Heterologous booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV (1·0×10^11 viral particles per mL; 0·2 mL)
Trial: 35605625
Drug: Homologous intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous intramuscular vaccination with CoronaVac (0·5 mL)
Trial: 35605625
Drug: Heterologous booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous booster vaccination with low dose aerosolised Ad5-nCoV
Trial: 35605625
Drug: Heterologous booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterologous booster vaccination with high dose aerosolised Ad5-nCoV
Trial: 35605625
Drug: Homologous intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous intramuscular vaccination with CoronaVac
Trial: 33087480
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (DexM) 2 µg/kg
Trial: 35562778
Drug: REALIST ORBCEL‐C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REALIST ORBCEL‐C (400 × 106 cells or maximal tolerated dose in phase 1)
Trial: 32224795
Drug: Single-treatment trial
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-treatment trial
Trial: 37335995
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nicotine gum
Trial: 34544468
Drug: Dose Painting
RxNorm normalized name: Castellani Paint
DrugBank: Phenol (DB03255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose Painting (DP) procedure with doses of 80, 85, and 91 Gy delivered to PTV1, PTV2, and PTV3 respectively.
Trial: 34544468
Drug: Three-Dimensional Conformal
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-Dimensional Conformal Radiation Therapy (3DCRT)
Trial: 34544468
Drug: Post-treatment follow-up
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment follow-up after 4 months
Trial: 33471654
Drug: 200,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200,000 IU intramuscular D2
Trial: 33471654
Drug: 400,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400,000 IU intramuscular D2
Trial: 33471654
Drug: 600,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600,000 IU intramuscular D2
Trial: 39515988
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel
Trial: 35474643
Drug: Pharmacist-based coaching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-based coaching (12 weekly face-to-face sessions)
Trial: 33998672
Drug: BIA 10‐2474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 10‐2474 (2.5–50 mg repeated oral doses for 10 days)
Trial: 33998672
Drug: BIA 10‐2474
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 10‐2474 (50 mg repeated administration)
Trial: 32683645
Drug: 30 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 months of dual antiplatelet therapy (DAPT)
Trial: 34049672
Drug: 12 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of dual antiplatelet therapy (DAPT)
Trial: 35700617
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (oral analgesics: acetaminophen q6h 1000 mg and NSAID, and sling if shoulder injury)
Trial: 34580169
Drug: Impedance cardiography
RxNorm normalized name: FAST-PAK ANGIOGRAPHY KIT WITH VASCORAY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impedance cardiography (ICG) guided treatment strategy
Trial: 38224135
Drug: Testosterone replacement
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone replacement therapy (TRT)
Trial: 36914946
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only (control group)
Trial: 35656720
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (TT)
Trial: 33645176
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (CT)
Trial: 35969882
Drug: Estrogen-alone therapy
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-alone therapy (from meta-analysis)
Trial: 32086889
Drug: Step-down pharmacotherapy
RxNorm normalized name: Kool-Down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step-down pharmacotherapy (n=67)
Trial: 32086889
Drug: Maintaining therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintaining therapy (n=68)
Trial: 34744069
Drug: Sling Suspension
RxNorm normalized name: fu ling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sling Suspension Therapy (SST)
Trial: 34920046
Drug: High-dose TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose TXA (≥50 mg/kg)
Trial: 34772753
Drug: Oral fixation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fixation device
Trial: 38418234
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy
Trial: 33737614
Drug: 450 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 g/kg iso-lipid test diet
Trial: 33737614
Drug: 550 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 550 g/kg iso-lipid test diet
Trial: 33737614
Drug: 500 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g/kg iso-lipid test diet
Trial: 32620339
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) 3 g/d for 28 days
Trial: 32444220
Drug: Allogeneic umbilical
RxNorm normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic umbilical cord blood infusion
Trial: 34287251
Drug: Traditional chemotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional chemotherapy setting
Trial: 35230058
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) - 5 consecutive daily 90-minute sessions at 2.0 atmospheres absolute with 100% oxygen
Trial: 33179515
Drug: Oral combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral combined estradiol (E2) and progesterone therapy
Trial: 35277071
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose iron and curcumin (FS65_Curc)
Trial: 35277071
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose iron and curcumin placebo (FS65_Plac)
Trial: 33864725
Drug: Oral allopurinol
RxNorm normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral allopurinol 300 mg twice daily
Trial: 37159610
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation therapy (CRT)
Trial: 33798310
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy (regulating menstruation and promoting pregnancy) at Baihui (GV 20), Shenting (GV 24), Guanyuan (CV 4), Sanyinjiao (SP 6), Shenshu (BL 23), Ciliao (BL 32), once a day, 5 times a week for 3 months.
Trial: 33798310
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (oral administration of climen, 1 tablet a day for 21 days, stopped for 1 week as a course, required 3 consecutive courses).
Trial: 34962984
Drug: Polypill plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill plus aspirin